Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Publication
, Journal Article
Kumar, SK; Callander, NS; Adekola, K; Anderson, LD; Baljevic, M; Baz, R; Campagnaro, E; Castillo, JJ; Costello, C; D'Angelo, C; Derman, B ...
Published in: J Natl Compr Canc Netw
January 2024
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2024
Volume
22
Issue
1D
Start / End Page
e240001
Location
United States
Related Subject Headings
- Waldenstrom Macroglobulinemia
- Oncology & Carcinogenesis
- Lymphoma, B-Cell
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljevic, M., Baz, R., … Kumar, R. (2024). Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 22(1D), e240001. https://doi.org/10.6004/jnccn.2024.0001
Kumar, Shaji K., Natalie S. Callander, Kehinde Adekola, Larry D. Anderson, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, et al. “Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 22, no. 1D (January 2024): e240001. https://doi.org/10.6004/jnccn.2024.0001.
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, et al. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Jan;22(1D):e240001.
Kumar, Shaji K., et al. “Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 22, no. 1D, Jan. 2024, p. e240001. Pubmed, doi:10.6004/jnccn.2024.0001.
Kumar SK, Callander NS, Adekola K, Anderson LD, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D’Angelo C, Derman B, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee H, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Snedeker J, Kumar R. Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Jan;22(1D):e240001.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
January 2024
Volume
22
Issue
1D
Start / End Page
e240001
Location
United States
Related Subject Headings
- Waldenstrom Macroglobulinemia
- Oncology & Carcinogenesis
- Lymphoma, B-Cell
- Humans
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis